Cadrenal Therapeutics Inc... (CVKD)
NASDAQ: CVKD
· Real-Time Price · USD
12.41
-0.51 (-3.95%)
At close: Aug 15, 2025, 12:50 PM
Company Description
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company.
The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation.
The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Cadrenal Therapeutics Inc. Common Stock
| Country | United States |
| IPO Date | Jan 20, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Quang X. Pham |
Contact Details
Address: 822 A1A North Ponte Vedra, Florida United States | |
| Website | https://www.cadrenal.com |
Stock Details
| Ticker Symbol | CVKD |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001937993 |
| CUSIP Number | |
| ISIN Number | US1276362076 |
| Employer ID | 88-0860746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Quang X. Pham | Chairman & Chief Executive Officer |
| Jeffrey Cole | Chief Operating Officer |
| Dr. James J. Ferguson FACC, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2025 | 8-K | Current Report |
| Aug 11, 2025 | 10-Q | Quarterly Report |
| Aug 05, 2025 | 8-K | Current Report |
| Jul 31, 2025 | ARS | Filing |
| Jul 31, 2025 | DEFA14A | Filing |
| Jul 31, 2025 | DEF 14A | Filing |
| Jul 18, 2025 | 8-K | Current Report |
| May 08, 2025 | 8-K | Current Report |
| May 08, 2025 | 10-Q | Quarterly Report |
| Apr 17, 2025 | 8-K | Current Report |